Human medicines European public assessment report (EPAR): Calquence, acalabrutinib, Date of authorisation: 05/11/2020, Revision: 12, Status: Authorised

6 July 2026

Human medicines European public assessment report (EPAR): Altuvoct, efanesoctocog alfa, Date of authorisation: 17/06/2024, Revision: 3, Status: Authorised

6 July 2026

Human medicines European public assessment report (EPAR): Tysabri, natalizumab, Date of authorisation: 27/06/2006, Revision: 53, Status: Authorised

6 July 2026

Agenda of the PRAC meeting 6-9 July 2026

6 July 2026

Human medicines European public assessment report (EPAR): Enhertu, trastuzumab deruxtecan, Date of authorisation: 18/01/2021, Revision: 20, Status: Authorised

6 July 2026

Agenda of the HMPC meeting 6-8 July 2026

6 July 2026

List of signals discussed at PRAC since September 2012

6 July 2026

Start of procedure: Type II Variation - Extension of indication under evaluation by the CHMP (22 May 2026 - 25 June 2026)

6 July 2026

Start of procedure: Extension of marketing authorisation (22 May 2026 - 25 June 2026)

6 July 2026

Human medicines European public assessment report (EPAR): Alprolix, eftrenonacog alfa, Date of authorisation: 12/05/2016, Revision: 12, Status: Authorised

6 July 2026